黄斑浮腫・黄斑変性治療薬の世界市場予測および分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 27
2.1 Related Reports 28
3 Disease Overview 29
3.1 Macular Degeneration Overview 29
3.1.1 Etiology and Pathophysiology 31
3.1.2 Classification 35
3.1.3 Symptoms and Diagnosis 37
3.2 Macular Edema Overview 40
3.2.1 Etiology and Pathophysiology 41
3.2.2 Classification 44
3.2.3 Symptoms and Diagnosis 45
4 Epidemiology – Macular Edema 48
4.1 Disease Background 48
4.2 Risk Factors and Comorbidities 48
4.3 Global Trends 49
4.3.1 US 50
4.3.2 5EU 50
4.3.3 Japan 51
4.4 Forecast Methodology 51
4.4.1 Sources Used 52
4.4.2 Sources Not Used 54
4.4.3 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 55
4.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetic Retinopathy 59
4.4.5 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 60
4.4.6 Forecast Assumptions and Methods – Total Prevalent Cases of ME following BRVO and CRVO 61
4.5 Epidemiological Forecast for Macular Edema (2013-2023) 62
4.5.1 Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 62
4.5.2 Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 64
4.5.3 Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 66
4.5.4 Total Prevalent Cases of ME Following BRVO 68
4.5.5 Age-Specific Total Prevalent Cases of ME Following BRVO 70
4.5.6 Sex-Specific Total Prevalent Cases of ME following BRVO 72
4.5.7 Total Prevalent Cases of ME Following CRVO 74
4.5.8 Age-Specific Total Prevalent Cases of ME Following CRVO 76
4.5.9 Sex-Specific Total Prevalent Cases of ME Following CRVO 78
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 81
4.6.3 Strengths of the Analysis 82
5 Epidemiology – Age-Related Macular Degeneration 83
5.1 Disease Background 83
5.2 Risk Factors and Comorbidities 84
5.3 Global Trends 85
5.3.1 US 85
5.3.2 5EU 86
5.3.3 Japan 86
5.4 Forecast Methodology 87
5.4.1 Sources Used 88
5.4.2 Forecast Assumptions and Methods 90
5.5 Epidemiological Forecast for AMD (2013-2023) 94
5.5.1 Total Prevalent Cases of AMD 94
5.5.2 Age-Specific Total Prevalent Cases of AMD 95
5.5.3 Sex-Specific Total Prevalent Cases of AMD 97
5.5.4 Age-Standardized Total Prevalence of AMD 99
5.5.5 Total Prevalent Cases of AMD by Stage 101
5.5.6 Total Prevalent Cases of Late AMD by Subtype 102
5.6 Discussion 104
5.6.1 Epidemiological Forecast Insight 104
5.6.2 Limitations of the Analysis 105
5.6.3 Strengths of the Analysis 106
6 Disease Management 107
6.1 Diagnosis and Treatment Overview 107
6.1.1 Macular Edema Diagnosis 107
6.1.2 Macular Degeneration Diagnosis 107
6.1.3 Treatment Guidelines and Leading Prescribed Drugs 108
6.1.4 Clinical Practice 110
6.2 US 123
6.3 France 127
6.4 Germany 130
6.5 Italy 133
6.6 Spain 136
6.7 UK 139
6.8 Japan 142
7 Competitive Assessment 145
7.1 Overview 145
7.2 Product Profiles – Major Brands 146
7.2.1 Lucentis (ranibizumab) 146
7.2.2 Eylea (aflibercept) 157
7.2.3 Avastin (bevacizumab) 168
7.2.4 Macugen (pegaptanib sodium) 175
7.2.5 Visudyne (verteporfin) 178
7.2.6 Corticosteroid Implants 183
8 Unmet Need and Opportunity 195
8.1 Overview 195
8.2 Treatment for Dry AMD 196
8.2.1 Unmet Need 196
8.2.2 Gap Analysis 198
8.2.3 Opportunity 200
8.3 Longer-Acting Anti-VEGF Drug Therapy 202
8.3.1 Unmet Need 202
8.3.2 Gap Analysis 204
8.3.3 Opportunity 204
8.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 205
8.4.1 Unmet Need 205
8.4.2 Gap Analysis 206
8.4.3 Opportunity 207
8.5 Less Invasive Drug Formulations 207
8.5.1 Unmet Need 207
8.5.2 Gap Analysis 208
8.5.3 Opportunity 209
8.6 Awareness and Earlier Patient Diagnosis 210
8.6.1 Unmet Need 210
8.6.2 Gap Analysis 211
8.6.3 Opportunity 211
8.7 Home Monitoring of AMD Progression 212
8.7.1 Unmet Need 212
8.7.2 Gap Analysis 213
8.7.3 Opportunity 214
9 Pipeline Assessment 216
9.1 Overview 216
9.2 Clinical Trial Mapping 217
9.3 Promising Drugs in Clinical Development 218
9.3.1 Abicipar pegol 220
9.3.2 Fovista 227
9.3.3 Squalamine 235
9.3.4 Lampalizumab 243
9.3.5 Emixustat 250
9.3.6 Optina 257
9.3.7 DE-102 265
9.4 Promising Drugs in Early-Stage Development 269
9.4.1 Complement Inhibitors 269
9.5 Other Drugs in Development 271
9.6 Biosimilars 273
10 Current and Future Players 275
10.1 Overview 275
10.2 Trends in Corporate Strategy 277
10.3 Company Profiles 278
10.3.1 Roche/Genentech 278
10.3.2 Novartis 282
10.3.3 Regeneron 285
10.3.4 Bayer 289
10.3.5 Valeant 293
10.3.6 Allergan 296
10.3.7 Alimera Sciences 299
10.3.8 Ampio Pharmaceuticals 303
10.3.9 Ophthotech 305
10.3.10 Acucela 309
10.3.11 Ohr Pharmaceuticals 313
11 Market Outlook 316
11.1 Global Markets 316
11.1.1 Forecast 316
11.1.2 Drivers and Barriers – Global Issues 324
11.2 US 327
11.2.1 Forecast 327
11.2.2 Key Events 333
11.2.3 Drivers and Barriers 333
11.3 France 335
11.3.1 Forecast 335
11.3.2 Key Events 341
11.3.3 Drivers and Barriers 341
11.4 Germany 345
11.4.1 Forecast 345
11.4.2 Key Events 350
11.4.3 Drivers and Barriers 350
11.5 Italy 353
11.5.1 Forecast 353
11.5.2 Key Events 360
11.5.3 Drivers and Barriers 360
11.6 Spain 364
11.6.1 Forecast 364
11.6.2 Key Events 369
11.6.3 Drivers and Barriers 369
11.7 UK 372
11.7.1 Forecast 372
11.7.2 Key Events 378
11.7.3 Drivers and Barriers 378
11.8 Japan 382
11.8.1 Forecast 382
11.8.2 Key Events 388
11.8.3 Drivers and Barriers 388
12 Appendix 392
12.1 Bibliography 392
12.2 Abbreviations 427
12.3 Methodology 434
12.4 Forecasting Methodology 434
12.4.1 Diagnosed ME and AMD Patients 434
12.4.2 Percentage of Drug-Treated Patients 435
12.4.3 Drugs Included in Each Therapeutic Class 435
12.4.4 Launch and Patent Expiry Dates 435
12.4.5 General Pricing Assumptions 436
12.4.6 Individual Drug Assumptions 437
12.4.7 Pricing of Pipeline Agents 442
12.5 Primary Research – KOLs Interviewed for this Report 443
12.6 Primary Research – High-Prescribers Survey 444
12.7 About the Authors 445
12.7.1 Analyst 445
12.7.2 Therapy Area Director 445
12.7.3 Epidemiologist 446
12.7.4 Global Head of Healthcare 446
12.8 About GlobalData 447
12.9 Disclaimer 447


【レポート販売概要】

■ タイトル:黄斑浮腫・黄斑変性治療薬の世界市場予測および分析
■ 英文:PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2014年10月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC111PIDR
■ 調査対象地域:グローバル
  • 電子メール暗号化の世界市場2016-2020
    About E-Mail Encryption E-mails are one of the most important modes of communication among employees of any organization. Confidential data of an organization is exchanged through e-mails over different networks. A number of wired and wireless networks are used for data transmission in an organization, and these networks are vulnerable to malware attacks. As e-mails carry an organization's confide …
  • 世界の熱媒体流体市場動向及び予測(~2019)
    Heat transfer fluids have found a wide acceptance in various industries, because of their distinguished properties. Based on application areas, the market of heat transfer fluids can broadly be segmented into oil & gas, concentrating solar power, chemical industry, manufacturing processes, pharmaceuticals, bio-diesel production, and others. Though oil & gas and concentrating solar power markets ar …
  • ヒトインスリンの世界市場:ヒトインスリン薬、ヒトインスリン・デリバリーデバイス
    The global human insulin market is poised to reach ~USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery dev …
  • 世界のポリカーボネート市場動向(2014-2018)
    TechNavio's analysts forecast the Global Polycarbonate market to grow at a CAGR of 5.05 percent over the period 2013-2018. One of the key factors contributing to this market growth is the expansion of production capacities by vendors. The Global Polycarbonate market has also been witnessing the increasing production of products with recycled polycarbonate content However, the decline of optical me …
  • 脂肪族アルコールの世界市場2019-2023
    About this market The emergence of China and India as manufacturing hubs is expected to have a positive influence on the fatty alcohols market. With these countries becoming important industrial hubs, demand for industrial and institutional cleaners is expected to increase and promote the market under review as fatty alcohols are widely used in cleaning products. Technavio’s analysts have predicte …
  • 鉄道車両リースの北米市場2017-2021
    ABSTRACTAbout Railcar Leasing The railcar leasing market is involved in the leasing of railcars to shippers, and rail freight operators. The contract term varies from 2 to 20 years. The contract is made under a given lease rate that provides the lessors with the expected amount of returns over the duration. The majority of railcars are private cars owned by the railcar leasing companies that are l …
  • インテリジェントネットワークの世界市場:用途別(情報認識、トラフィック予測・分類、リソース管理・ネットワークの採択、パフォーマンス予測・コンフィギュレーションの外挿)、エンドユーザー別、サイズ別、地域別予測
    Global Intelligent Network Market to reach USD 10 billion by 2025. Global Intelligent Network Market valued approximately USD 1.16 billion in 2016 is anticipated to grow with a healthy growth rate of more than 27% over the forecast period 2017-2025. information cognition is expected to have a larger market share during the forecast period, as there is an increasing need for information cognition f …
  • ヨーロッパのスパ(温泉)市場2016-2020
    About SpaThe spa market in Europe contributed about 40% of the global spa market by retail value in 2015. Countries in Western Europe experienced healthy growth despite unfavorable economic environment. Specialized urban spas and boutique hotels in the region offer differentiated services to customers at different pricing options. Rising investments in the hospitality and spa sector have significa …
  • 世界の動物飼料用酸化防止剤(Animal Feed Antioxidants)市場動向(2012-2016)
    TechNavio's analysts forecast the Global Animal Feed Antioxidants market to grow at a CAGR of 5.07 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing concern about animal health and feed safety. The Global Animal Feed Antioxidants market has also been witnessing an increasing demand for natural antioxidants. However, the impact of global …
  • グローバル小売市場におけるトップ10企業分析
    Synopsis The Conlumino Global Top 10 Retail Companies: Company Guide is a crucial resource for anyone looking to gain information on the top companies in the global retailers industry. Detailed company profile and SWOT analysis information is provided for all the leading companies who are ranked in order by total annual revenues generated. Wal-Mart Stores, Inc. Costco Wholesale Corporation Tesco P …
  • 遺伝子治療の世界市場:研究開発および売上予測2016-2026
    Gene Therapies – Discover Revenue Predictions and See How Treating Cancer, Cardiovascular Disorders and Other Chronic Diseases Progresses What does the future hold for gene therapy? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities. Visiongain’s …
  • BRIC新興国の末梢血管処置動向(~2020)
    BRIC Peripheral Vascular Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Peripheral Vascular Procedures Outlook to 2020", provides key procedures data on the BRIC Peripheral Vascular Procedures. The report provides procedure volumes within market categories – Thrombectomy Procedures, PTA Drug Eluting Balloon (DEB) Angioplasty Procedures, Inferior Vena Cava Filters (IVCF) Procedur …
  • Sinopec International Petroleum to Acquire Minority Stake in Three Oil and Gas Companies from Tiptop Energy and Sinopec Overseas
    Sinopec International Petroleum to Acquire Minority Stake in Three Oil and Gas Companies from Tiptop Energy and Sinopec Overseas for US$3 Billion: The Deal will Increase Sinopec Corp’s Overseas Reserves and Production - Deal Analysis from GlobalData Summary Sinopec International Petroleum E&P Hongkong Overseas Ltd. (SIP), a joint venture between China Petroleum & Chemical Corporation (Sinopec Corp …
  • 転移性腎細胞癌:グローバル臨床試験レビュー(2014年上半期)
    Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Renal Cell Carcinoma. It includes …
  • 2014 World Animal Health Market Outlook and Leading Supplier Business Strategies and Marketing Tactics
    This new 80-page report from Venture Planning Group analyzes business strategies and marketing tactics of the world’s leading animal health companies, including: Five-year forecasts for: - Major market segments - Key geographic regionsAssessment of major U.S. and international trends with potentially significant impact on the animal health industry during the next five years, inclu …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。